Chimeric antigen receptor dendritic cells suppress melanoma growth in preclinical cancer models
CAR-DCs could be an effective strategy for therapies against solid tumors that should be further explored. The approach relies on the antigen-presenting ability of DCs and their role in T cell activation and can be coupled with checkpoint inhibition in place of monoclonal antibody treatment.
Authors
- Takuya Tada (ORCID: https://orcid.org/0000-0003-0779-9954)
- Nathaniel R. Landau (ORCID: https://orcid.org/0000-0002-9997-1004)
- Julia Minnee (ORCID: https://orcid.org/0009-0003-3340-9670)
- Ruofan Li (ORCID: https://orcid.org/0000-0001-7746-9569)
- Wallace ZH Wong
- Jose LM Semana
- Benjamin S Russell
Institutions
- New York University (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2025-013040
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health